Cellectar Biosciences, Inc. (CLRB): Nasdaq/NYSE listing notice — Cellectar receives Nasdaq minimum bid price deficiency notice; 180-day cure period until July 29, 2025

Cellectar Biosciences, Inc.

Notice from Nasdaq on Jan 30, 2025 for failure to maintain $1.00 minimum bid price per Nasdaq Listing Rule 5550(a)(2).
No immediate impact on listing; common stock remains on Nasdaq Capital Market.
Company has 180 calendar days, until July 29, 2025, to regain compliance.
If not cured, Company may be eligible for an additional 180-day extension subject to meeting other listing standards.
Failure to regain compliance could lead to delisting; Company may request a hearing to stay any delisting action.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Cellectar Biosciences, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

January 30, 2025, Cellectar Biosciences, Inc. (the “Company”) received notice from Nasdaq which indicated that under Nasdaq Listing Rule 5550(a)(2), the Company is required to maintain a minimum bid price for its common

View on SEC.gov

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Cellectar Biosciences, Inc. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: noncompliance notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

January 30, 2025, Cellectar Biosciences, Inc. (the “Company”) received notice from Nasdaq which indicated that under Nasdaq Listing Rule 5550(a)(2), the Company is required to maintain a minimum bid price for its common stock of $1.00 for continued listing. The notice does not have any immediate impact on the listing of the Company’s stock on the Nasdaq exchange. The Company’s common stock remains listed on the Nasdaq Capital Market. In accordance with the Nasdaq Listing Rules, the Company has 180 calendar days, or until July 29, 2025, to regain compliance with the bid price requirement. In th

View on SEC.gov

Browse all listing & compliance notices →

Cellectar Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-25-008127

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.